Mycophenolate mofetil and systemic lupus erythematosus

Lupus

Volumn 15, Issue 11_suppl, 2006, Pages 44-54

  Doria, A ^a   Iaccarino, L ^a   Arienti, S ^a   Rampudda, M E ^a   Canova, M G ^a   Rondinone, R ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

immunosuppressants; lupus nephritis; mycophenolate mophetil; prognosis; secondary prevention; systemic lupus erythematosus; therapy

Indexed keywords

MYCOPHENOLATE MOFETIL;

DISEASE ACTIVITY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; DRUG USE; HEMATOLOGIC DISEASE; HUMAN; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84994335383     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203306071671     Document Type: Review

References (94)

1. Warrens AN., The evolving role of mycophenolate mofetil in renal transplantation. Q J Med 2000; 93: 15-20.
2. Moder KG., Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90: 15-19.
3. Doria A, Iaccarino L, Ghirardello A, et al.Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700-706.
4. Zandman-Goddard G, Shoenfeld Y., Infections and SLE. Autoimmunity 2005; 38: 473-485.
5. Pisoni CN, Sanchez FJ, Karim Y, et al.Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-1052.
6. Riskalla MM, Somers EC, Fatica RA, McCune WJ., Tolerability of mycophenalte mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1508-1512.
7. Glicklich D, Acharya A., Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney 1998; 32: 318-322.
8. Karim MY, Alba P, Cuadrado MJ, et al.Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 2002; 41: 876-882.
9. Natsumeda Y, Ohno S, Kawasaki H, et al.Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990; 265: 5292-5295.
10. Konno Y, Natsumeda Y, Nagai M, et al.Expression of IMP dehydrogenase types I and II in Escherichia coli and distribution in normal lymphocytes and leukeumic cell lines. J Biol Chem 1991; 266: 506-509.
11. Nagai M, Natsumeda Y, Weber G., Proliferation linked regulation of the type II IMP dehydrogenase gene in human normal lyphocytes and HL-60 leukemic cells. Cancer Res 1992; 52: 258-261.
12. Allison AC, Eugui EM., Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
13. Cohn RG, Mirkovic A, Caulfield J, Eugui EM., Apoptosis of human activated peripheral T-cells and T-lymphocytic and promonocytic cell lines induced by mycophenolic acid, the active metabolite of CellCept. In The sixth Basic Sciences Symposium of the Transplantation Society, 1999: 173.
14. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM., Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine syntesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25 (Suppl 2): 67-70.
15. Senda M, De Lustro M, Eugui E, Natsumeda Y., Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995; 60: 1143-1148.
16. Allison AC., Mechanism of action of MMF. Lupus 2005; 14: S2-S8.
17. Allison AC, Almquist SJ, Muller CD, Eugui EM., In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant Proc 1991; 23 (Suppl 2): 10-14.
18. Haug C, Schmid-Kotsas A, Linder T, et al.The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clin Sci (Lond) 2002; 103 (Suppl 48): 76S-80S.
19. Dubus I, Vendrely B, Christophe I, et al.Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 2002; 62: 857-867.
20. Pescovitz MD, Conti D, Dunn J, et al.Intravenous mycophenolate mofetil (MMF): safety, tolerability, and pharmacokinetics. Clin Transplant 2000; 14: 179-188.
21. Nowak I, Shaw LM., Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995; 41: 1011-1017.
22. Bullingham RE, Nicholls AJ, Kamm BR., Clinical pharmacokinetics of mycphenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.
23. Bullingham RE, Nicholls A, Hale M., Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transpant Proc 1996; 28: 925-929.
24. Ensom MH, Partovi N, Decarie D, Ignaszewski AP, Fradet GJ, Levy RD., Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother 2003; 37: 1761-1767.
25. Glander P, Hambach P, Braun KP, et al.Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003; 41: 470-476.
26. Neumann I, Haidinger M, Jäger H, et al.Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003; 14: 721-727.
27. Shaw LM, Kaplan B, DeNofrio D, et al.Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000; 22: 14-19.
28. Yeoung S, Tong WK, Tsang HL, et al.Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc 2001; 33: 1052-1053.
29. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM., Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant treated with concomitant tacrolimus. Clin Chem 2002; 48. 1497-1504.
30. Kuypers DRJ., Immunosuppressive drug monitoring-what to use in clinical practice today to improve renal graft outcome. Transpl Int 2005; 18: 140-150.
31. McMurray RW, Elbourne KB, Lagoo A, Lal S., Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 1998; 25: 2364-2370.
32. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH., Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 116: 534-541.
33. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G., Mycophenolate mofetil limts renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583-1589.
34. Ramos MA, Pinera C, Setien MA, et al.Modulation of autoantibody production by mycophenolate mofetil: effects of the development of SLE in (NZB × NZW)F1 mice. Nephron Dial Transplant 2003; 18: 878-883.
35. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D., Long-term followup of lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885.
36. Briggs WA, Choi MG, Scheel PJ Jr,. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213-217.
37. Dooley MA, Cosio FG, Nachman PH, et al.Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-839.
38. Li L, Wang H, Lin S, et al.Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi 2002; 41: 476-479.
39. Kingdon EJ, McLean AG, Psimenou E, et al.The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-611.
40. Ding L, Zhao M, Zou W, Liu Y, Wang H., Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 2004; 13: 113-118.
41. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM., Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 2004; 43: 377-380.
42. Ferro ML, Karim MY, Abbis IC, D'Cruz DP, Khamashta MA, Hughes GRV., Mycophenolate mofetil: a potential treatment for reducing proteinuria associated with membranous lupus nephritis. Arthritis Rheum 2003; 48: S588.
43. Borba EF, Guedes LK, Christmann RB, Figueiredo CP, Gonçalves CR, Bonfà E., Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 2006 May 31 (Epub ahead of print).
44. Hu W, Liu Z, Chen H, et al.Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002; 115: 705-709.
45. Chan TM, Li FK, Tang CS, et al.Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong- Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
46. Falk RJ., Treatment of lupus nephritis-a work in progress. New Engl J Med 2000; 343: 1182-1183.
47. Chan TM, Wong WS, Lau CS, et al.Follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil. J Am Soc Nephrol 2001; 12: 195A (abstract).
48. Chan TM, Tse KC, Tang CS, Mok MY, Li FK., Long term study of mycophenolate mofetil as continuous induction and manteinance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
49. Contreras G, Pardo V, Leclercq B, et al.Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
50. Ong LM, Hooi LS, Lim TO, et al.Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10: 504-510.
51. Ginzler EM, Dooley MA, Aranow C, et al.Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
52. Boumpas DT, Austin HA 3rd, Vaughn EM, et al.Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
53. Illei GG, Austin HA, Crane M, et al.Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
54. Illei GG, Takada K, Parkin D, et al.Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressve therapy. Long-term follow-up of a cohort of 145 patients participating in randomized controlled trials. Arthritis Rheum 2002; 46: 995-1002.
55. Gourley MF, Austin HA 3rd, Scott D, et al.Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
56. Briani C, Zara G, Rondinone R, et al.Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity 2005; 38: 549-555.
57. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W., Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-736.
58. Schanz S, Ulmer A, Rassner G, Fierlbeck G., Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002; 147: 174-178.
59. Goyal S, Nousari HC., Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45: 142-144.
60. Boehm I, Bieber T., Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001; 137: 235-236.
61. Hanjani NM, Nousari CH., Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002; 138: 1616-1618.
62. Cetkovska P, Pizinger K., Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil. Int J Dermatol 2006; 45: 320-322.
63. Pisoni CN, Obermoser G, Cuadrado MJ, et al.Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005; 23: 393-396.
64. Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus, 6th edition Lippincot Williams & Wilkins, 2002: 803-805.
65. Vasoo S, Thumboo J, Fong KY., Refractory immune thrombocytopenia in systemic lupus erythemeatosus: response to mycophenolate mofetil. Lupus 2003; 12: 630-632.
66. Chang HK., Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J Korean Med Sci 2005; 20: 883-885.
67. Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM., Autoimmune haemolytic anaemia in patients with systemic lupus erythematosus. Am J Med 2000; 108: 198-204.
68. Asano Y, Maeda M, Uchida N, et al.Immunosuppressive therapy for patients with refractory anemia. Ann Haematol 2001; 80: 634-638.
69. Avina-Zubieta JA, Galindo-Rodriguez G, Robledo I, et al.Long-term effectiveness of danazol, corticosteroid and cytotoxic drugs in the treatment of haematologic manifestation of systemic lupus erythematosus. Lupus 2003; 12: 52-57.
70. Rivero SJ, Alger M, Alarçon-Segovia D., Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. Arch Intern Med 1979; 139: 773-776.
71. Alba P, Karim MY, Hunt BJ., Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003; 12: 633-635.
72. Howard J, Hoffbrand AV, Prentice HG, Metha A., Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002; 117: 712-715.
73. Samad AS, Lindsley CB., Treatment of pulmonary hemorrage in childhood systemic lupus erythematosus with mycophenolate mofetil. South Med J 2003; 96: 705-707.
74. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF., Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3: 1550-1559.
75. Guo H, Leung JCK, Chan LYY, Lui SL, Tsang AWL, Lai KN., Modulation of intra-pulmonary TGF-β expression by mycophenolate mofetil in lupus prone MRL/lpr mice. Lupus 2005; 14: 583-592.
76. Blanco FJ, Gomez-Reino JJ, de la Mata J, et al.Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus 1998; 7: 159-163.
77. Grisanti M, Nader A, Caciuttolo R., Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid sindrome: successful treatment with mycophenolate mofetil. Lupus 2001; 10: S31 (abstract 76).
78. Jose J, Paulose BK, Vasuki Z, Danda D., Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus. Indian J Med Sci 2005; 59: 353-356.
79. Opelz G, Dohler B., Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-30.
80. Bernatsky S, Ramsey-Goldman R, Rajan R, et al.Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1507-1509.
81. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplant. Transplantation 1996; 61: 1029-1037.
82. Robson R, Cecka JM, Opelz G, Budde M, Sacks S., Prospective registrybased observational study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transpl 2005; 5: 2954-2960.
83. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296-303.
84. Snanoudj R, Durrbach A, Leblond V, et al.Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplanatation 2003; 76: 930-937.
85. Dasgupta N, Gelber AC, Racke F, Fine DM., Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 2005; 14: 910-913.
86. Doria A, Shoenfeld Y, Wu R, et al.Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-1077.
87. Ramsey-Goldman R, Dunn JE, Huang CF, et al.Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42: 882-890.
88. Gorgos L, Goldman D, Petri M., The ACR/SLICC damage index in systemic lupus erythematosus (SLE). Arthritis Rheum 1993; 36: S68.
89. Rinaldi S, Doria A, Salaffi F, et al.Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology 2004; 43: 1574-1579.
90. Doria A, Rinaldi S, Ermani M, et al.Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology 2004; 43: 1580-1586.
91. Swaak AJG, Bronsveld W, Nieuwenhuys EJ, Nossent JC, Smeenk RJT., Systemic lupus erythematosus-changing disease patterns in the disease course. Dutch experience with 110 patients studied prospectively. Rheumatol Int 1991; 10: 241-244.
92. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Eng J Med 1991; 324: 150-154.
93. Tsakonas E, Joseph L, Esdaile JM, et al.A long-term study of hydoxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998, 7: 80-85.
94. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CGM., Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 534-539.